Petiq acquired by Bansk Group
Context
Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO. The existing executive management team will continue to operate the business independently. The strategic rationale centres on accelerating PetIQ's mission of providing convenient and affordable pet healthcare, investing in marketing and innovation, and pursuing strategic bolt-on acquisitions — initiatives that Bansk believes are better executed outside the constraints of public market ownership.
Petiq, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, standing directly in line with the average observed in the Healthcare & Pharma sector (15.6x in 2024).
-> Deep-dive in Healthcare & Pharma market trends
Target
PetIQ is a leading US-based pet medication, health and wellness company, operating across two complementary business segments: (1) a product division, which develops, manufactures, and distributes branded and third-party pet medications as well as health and wellness items through retail and e-commerce channels, with world-class manufacturing facilities located in Omaha (Nebraska), Springville (Utah), and Daytona Beach (Florida); and (2) a veterinary services division, which operates over 2,600 mobile community clinic locations and wellness centers hosted at retail partner locations across 39 US states, providing convenient and affordable access to veterinary care for pet owners.
Ent. Value
$1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (USD)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 12/2024 | UI INVESTISSEMENT | DIDACTIC | FRANCE | Medical Consumables |
| 11/2024 | NAXICAP PARTNERS | GLOBAL D | FRANCE | Implants & Prosthetics |
| 10/2024 | CLAYTON, DUBILIER & RICE (CD&R) | OPELLA | FRANCE | Generics / Labs |
| 10/2024 | KKR / KREFELD | ANJAC BEAUTY & HEALTH | FRANCE | CDMO |
| 09/2024 | AGILENT TECHNOLOGIES | BIOVECTRA | CANADA | CDMO |
| 08/2024 | NORDSON CORPORATION | ATRION CORPORATION | UNITED STATES | Diagnostic Equipment |
| 08/2024 | RECURSION PHARMACEUTICALS | EXSCIENTIA | UNITED KINGDOM | R&D Biotech |
| 07/2024 | ASTORG | NEXPRING HEALTH EX HAMILTON THORNE | UNITED STATES | Medical Devices |
| 07/2024 | ROCHE | LUMIRADX | UNITED KINGDOM | Diagnostic Equipment |
| 05/2024 | BRUKER | ELITECH GROUP | FRANCE | Diagnostic Equipment |
REFERENCES
Valuation range: EV $1–10bn
Revenue range: $1–10bn
EBITDA range: $100–200M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Petiq by Bansk Group are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: bansk group
FAQ
What transaction does this page cover?
How was the acquisition of Petiq by Bansk Group valued, and what multiples were paid?
What were Petiq’s revenue and EBITDA at the time of the deal?
How does the valuation of Petiq compare to benchmarks in the Healthcare & Pharma sector?
What sources support the information on this transaction?
What is mynth?